AI Summary
The content discusses a study focused on investigating treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair (HRR) genes, particularly BRCA1/2. While germline BRCA mutations have been linked to poor outcomes in prostate cancer, the association between somatic/germline alterations in HRR genes and treatment outcomes in metastatic castration-resistant prostate cancer is not well understood. The study aims to explore the prevalence and outcomes related to HRR alterations, focusing on patients starting first-line treatment for metastatic castration-resistant prostate cancer with androgen receptor signaling inhibitors or taxanes.
Although germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations in homologous recombination repair (HRR) genes and treatment outcomes in metastatic castration-resistant PC (mCRPC) is limited.The aim of this study was to investigate the prevalence and outcomes associated with somatic/germline HRR alterations, particularly BRCA1/2, in patients initiating first-line (1L) mCRPC treatment with androgen receptor signalling inhibitors (ARSi) or taxanes.